Form D · Biotechnology

ARVINAS, INC.

New Haven, CT · CIK 0001655759

Offering snapshot reported Jul 19, 2019 · SEC filing

Reported sold
$32.5M
Offering amount: $32.5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 16, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 19, 2019Initial$32,499,996No comparison1SEC filing
Apr 5, 2018Initial$55,000,000No comparison22SEC filing
Oct 23, 2015Initial$41,609,999No comparison16SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-344713

Source: Form D, filed Jul 19, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Sean Cassidy Executive
John G. Houston Director, Executive
Edward Kennedy, Jr. Director
Andrew Levin Director
Manuel Litchman Director, Executive
Jakob Loven Director
Bradley Margus Director
Brad Margus Director
Briggs Morrison Director
Kush Parmar Director
Liam Ratcliffe Director
Timothy Shannon Director
Tim Shannon Director
Jonathan Soderstrom Director
Stephen Squinto Director
Ian Taylor Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
395 Winchester Ave 5 Science Park
New Haven, CT, 06511